Evaluation of short-term COVID-19 vaccines adverse events following immunization severity as reported by Iraqi consumers

  • Ban Al-Shimran Iraqi Pharmacovigilance Center, Ministry of Health, Baghdad, Iraq.
  • Manal M. Younus Iraqi Pharmacovigilance Center, Ministry of Health, Baghdad, Iraq.
  • Balqees Salih Al-Rusafa Health Directorate, Ministry of Health, Baghdad, Iraq.
Keywords: COVID-19 Vaccines, Pharmacovigilance, Self-Assessment, Severity, AEFI, Patient Engagement


Introduction: Consumer-generated Adverse Events Following Immunization (AEFI) reports are a major source of vaccine safety information in pharmacovigilance, which was unprecedented within the Iraqi settings.

Methods: A self-assessment form was developed to be accessed by the consumers country-wide via the Iraqi pharmacovigilance center’s (IPvC) WhatsApp number. A retrospective analysis was then performed on the responses submitted from April 2021 until April 2022. Different independent variables were analyzed for their influence on subjective AEFI severity.

Results: 2843 responses were finally included. The average number of reported AEFI was 4.03 (S.D. ± 2.58) per response and significantly different among vaccine types. Both Comirnaty and Vaxzevria-associated AEFIs were reported to affect daily life similarly (~59 %), while Sinopharm was 42.4 %. Treatment-seeking was highest in Vaxzervria reports (22.8 %). Factors associated with higher reported severity include; younger people, females, and previous COVID-19 infection. Also, for the Comirnaty vaccine, the second dose. Fever, body rash, and difficulty breathing were the most significantly associated with treatment-seeking. A very small number of serious AEFIs were also detected.

Conclusion: Consumer reporting is valuable for generating data regarding COVID-19 vaccines’ AEFIs within the Iraqi spontaneous surveillance system and their engagement is recommended in the future for other medicinal products as well.

Author Biography

Ban Al-Shimran, Iraqi Pharmacovigilance Center, Ministry of Health, Baghdad, Iraq.

Iraq Ministry of Health


Aryal, S., Devbhandari, R. P., Shrestha, A., Rajbhandari, P., Shakya, T., Tuladhar, S., Maharjan, S., Bashyal, R., Suwal, R., Mishra, D., Jha, R. K., & Shrestha, S. (2021). Adverse events following immunization with Sinopharm (Vero Cell), inactivated COVID-19 vaccine. Journal of Patan Academy of Health Sciences, 8(2), 18–24.

Ban Abdulameer AL-Shimran, M.M.Y., Qaragholi, A.R.A. (2022). COVID-19 VACCINES Adverse Events Following Immunization Surveillance Report: A Year of Vaccinovigilance. Iraqi New Medical Journal,8(15):9–14.

Bhandari, B., Rayamajhi, G., Lamichhane, P., & Shenoy, A. K. (2022). Adverse Events following Immunization with COVID-19 Vaccines: A Narrative Review. BioMed research international, 2022, 2911333.

Inácio, P., Cavaco, A., & Airaksinen, M. (2017). The value of patient reporting to the pharmacovigilance system: a systematic review. British journal of clinical pharmacology, 83(2), 227–246.

Iraq CoronaVirus Statistics Worldometer. (2022). Available from: https://www.worldometers.info/coronavirus/country/iraq/

Jeon, M., Kim, J., Oh, C. E., & Lee, J. Y. (2021). Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System. Journal of Korean medical science, 36(17), e114.

John, M., Kelso, M. (2022). COVID-19: Allergic reactions to SARS-CoV-2 vaccines. In: N Franklin Adkinson, Jr M, Anna M Feldweg M, editors. UpToDate. Retrieved from: https://www.uptodate.com/contents/covid-19-allergic-reactions-to-sars-cov-2-vaccines

Joshi, R. K., Muralidharan, C. G., Gulati, D. S., Mopagar, V., Dev, J. K., Kuthe, S., Rather, A. A., & Sahoo, A. K. (2021). Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. Medical journal, Armed Forces India, 77(Suppl 2), S505–S507.

Kadhim, K. (2015). Self-Reporting of Adverse Drug Reactions in Iraqi Hospitals: Patient’s Perspectives. Pharmacol Pharm, 6(12):566–72.

Kaur, U., Ojha, B., Pathak, B. K., Singh, A., Giri, K. R., Singh, A., Das, A., Misra, A., Yadav, A. K., Kansal, S., & Chakrabarti, S. S. (2021). A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine, 38, 101038.

Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., Mangino, M., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet. Infectious diseases, 21(7), 939–949.

Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European review for medical and pharmacological sciences, 25(3), 1663–1669.

Mohammed, S. I., & Abdul Al-razaq, A. F. (2017). Knowledge and attitude of Iraqi pharmacists in Baghdad community toward an adverse drug reactions monitoring. Asian Journal of Pharmaceutical and Clinical Research, 10(4), 219–222.

Nadeem, I., Ul Munamm, S. A., Ur Rasool, M., Fatimah, M., Abu Bakar, M., Rana, Z. K., Khatana, U. F., Jordon, L., Saqlain, M., Mahdi, N., & McLoughlin, H. (2022). Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan. Postgraduate medical journal, 141649. Advance online publication.

Niebel, D., Novak, N., Wilhelmi, J., Ziob, J., Wilsmann-Theis, D., Bieber, T., Wenzel, J., & Braegelmann, C. (2021). Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective. Vaccines, 9(9), 944.

Ossato, A., Tessari, R., Trabucchi, C., Zuppini, T., Realdon, N., & Marchesini, F. (2021). Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. European journal of hospital pharmacy : science and practice, ejhpharm-2021-002933. Advance online publication

Ratneswaren A. (2020). The I in COVID: The importance of community and patient involvement in COVID-19 research. Clinical medicine (London, England), 20(4), e120–e122.

Rolfes, L., van Hunsel, F., van der Linden, L., Taxis, K., & van Puijenbroek, E. (2017). The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis. Drug safety, 40(7), 607–614.

Saeed, B. Q., Al-Shahrabi, R., Alhaj, S. S., Alkokhardi, Z. M., & Adrees, A. O. (2021). Side effects and perceptions following Sinopharm COVID-19 vaccination. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 111, 219–226.

Salih, M., Abd, A.Y., Al-lela, O.Q.B., Elkalmi, R., Kurmanji, J. (2016). Physicians’ knowledge about pharmacovigilance in Iraq. Journal of Pharmacovigilance, 4(3): 1000214

Shahin, W., Kennedy, G.A., Stupans, I. (2019). The impact of personal and cultural beliefs on medication adherence of patients with chronic illnesses: a systematic review. Patient Prefer Adherence, 13:1019-1035.

Sharrad, A. (2017). Pharmacists’ Knowledge, Attitude and Practice about Adverse Drug Reaction in Basra/Iraq. International Journal of Pharmaceutical Sciences and Research, 8(5):1000–6.

Vigezzi, G. P., Lume, A., Minerva, M., Nizzero, P., Biancardi, A., Gianfredi, V., Odone, A., Signorelli, C., & Moro, M. (2021). Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: results from a cross-sectional survey among staff of a large Italian teaching hospital. Acta bio-medica : Atenei Parmensis, 92(S6), e2021450.

Watson, S., Chandler, R. E., Taavola, H., Härmark, L., Grundmark, B., Zekarias, A., Star, K., & van Hunsel, F. (2018). Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Drug safety, 41(2), 203–212.

Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., & Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC medicine, 19(1), 173.

Zhang, Y., Belayachi, J., Yang, Y., Fu, Q., Rodewald, L., Li, H., Yan, B., Wang, Y., Shen, Y., Yang, Q., Mu, W., Tang, R., Su, C., Xu, T., Obtel, M., Mhayi, A., Razine, R., Abouqal, R., Zhang, Y., & Yang, X. (2022). Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC public health, 22(1), 1584.

How to Cite
Al-Shimran B, Younus M, Salih B. Evaluation of short-term COVID-19 vaccines adverse events following immunization severity as reported by Iraqi consumers. jpadr [Internet]. 2023Mar.1 [cited 2023Mar.26];4(1):5-14. Available from: https://jpadr.com/index.php/jpadr/article/view/114